Longevity Protocols for Adults Over 35:
What the Evidence Actually Supports

No single longevity intervention has a stronger or broader evidence base. Resistance training preserves muscle mass against age-related sarcopenia, improves insulin sensitivity, stimulates bone remodeling, reduces systemic inflammation via anti-inflammatory myokines, supports testosterone levels, and is consistently associated with reduced cardiovascular mortality independent of body weight.

For adults over 35, resistance training is foundational — not optional. 2–3 sessions per week is the effective minimum. Progressive overload (gradually increasing resistance) is the key training principle. Cardio complements it but should not displace it in a longevity protocol after 35.

Sleep is the foundational recovery system. Growth hormone is secreted primarily during deep slow-wave sleep. Chronic sleep restriction consistently raises cortisol, suppresses testosterone, increases inflammatory markers, impairs insulin sensitivity, and accelerates multiple aging pathways. Even modest chronic restriction (6 hours vs 8) produces measurable metabolic and cognitive impairment.

Consistent sleep and wake times — even on weekends — anchor circadian rhythm, which independently regulates dozens of hormonal and metabolic processes. A dark, cool sleep environment and limited light exposure in the evening are the highest-leverage behavioral changes in any longevity protocol for adults over 35.

Due to anabolic resistance — the reduced muscle protein synthesis response to protein stimulation in older muscle — adults over 35 require significantly more dietary protein to maintain muscle mass than younger people. Research supports 1.2–1.6g per kg of body weight daily for adults doing resistance training, with evidence for up to 2.0g/kg in active muscle-building phases.

Protein distribution across meals matters as much as total intake. Meals of 25–35g protein per sitting trigger maximal muscle protein synthesis. This is especially critical during GLP-1 therapy, when appetite suppression can cause severe undereating and accelerate muscle loss — the most preventable downside of weight loss medication.

Zone 2 exercise — sustained aerobic work where you can hold a conversation but are breathing harder than normal — is the primary stimulus for mitochondrial biogenesis. Mitochondrial dysfunction is one of the core hallmarks of aging. Zone 2 is the most efficient way to improve mitochondrial health, metabolic flexibility, and cardiovascular capacity in adults over 35.

150+ minutes per week is the evidence-based minimum. Brisk walking qualifies. Zone 2 and resistance training are complementary — one does not substitute for the other in a complete longevity protocol.

Creatine monohydrate generates near-universal agreement among longevity researchers as the supplement with the best evidence-to-cost ratio. In adults over 35, it supports muscle protein synthesis, cognitive function, and cellular energy metabolism. It is safe, inexpensive, and extensively studied across decades. Longevity benefits extend well beyond athletic performance — creatine appears to support brain health and may attenuate age-related cognitive decline.

3–5g daily is the effective dose. Timing is flexible. No loading phase needed for long-term use. Use creatine monohydrate specifically — not creatine HCl or other proprietary forms that charge a premium for no demonstrated benefit.

Omega-3 fatty acids have robust evidence for reducing systemic inflammation, supporting cardiovascular health, and modestly improving body composition outcomes combined with resistance training. The anti-inflammatory effects are particularly relevant for adults over 35 experiencing inflammaging. Most Western diets are significantly deficient in EPA and DHA relative to omega-6 intake.

Quality varies significantly between products. Look for third-party tested fish oil or algae-based (for vegetarians) sources with verified EPA and DHA content. An omega-3 index blood test is the most accurate way to calibrate your supplementation dose.

NAD+ levels decline with age — a well-established phenomenon. NMN and NR reliably raise blood NAD+ levels in humans, confirmed by multiple clinical trials. A 1,000mg single oral dose of NR raised blood NAD+ 2.7-fold in one study. Human studies show NR has positive effects on vascular endothelial function and mitochondrial health in healthy adults.

The important nuance: raising NAD+ levels has been demonstrated. Whether this translates to meaningful healthspan extension in humans is still being established. The mechanism is sound and preclinical evidence is strong — but long-term human outcome data is limited. A reasonable addition to longevity protocols for adults over 35 after Tier 1 foundations are solid.

Metformin activates AMPK — a cellular energy sensor that mimics some effects of caloric restriction — and suppresses mTOR, a pathway linked to accelerated aging when chronically over-activated. Observational studies consistently show diabetic patients on metformin outliving non-diabetic controls not on the drug. The TAME trial (Targeting Aging with Metformin) is running the first randomized controlled trial of metformin for longevity specifically in non-diabetic adults — results pending.

Key caveat: metformin may blunt training adaptations when taken close to exercise. Skipping on workout days is a common protocol among longevity physicians who prescribe it. Requires prescription and monitoring of B12 levels with long-term use.

Rapamycin inhibits mTOR — a central regulator of cellular growth and aging. It is the most reliable lifespan extender across multiple animal species. The 2025 PEARL trial (48-week, randomized, placebo-controlled) found low-dose intermittent rapamycin was relatively safe in healthy adults, with significant improvements in lean tissue mass and pain in women at 10mg weekly. A 2025 pilot study found short-term mTOR inhibition improved cardiac and endothelial function in older men.

Rapamycin is FDA-approved as an immunosuppressant. Off-label longevity use at lower, intermittent doses is gaining traction among longevity physicians. This remains experimental territory — honest longevity researchers say so plainly. Long-term human safety data at longevity doses is still accumulating. Do not pursue this without an experienced physician who can monitor you.

GLP-1 medications are increasingly recognized in longevity medicine beyond weight loss. The SELECT trial demonstrated a 20% reduction in major cardiovascular events over 4 years with semaglutide. GLP-1 receptors in the heart, kidneys, and brain mean the benefits extend well beyond appetite suppression and body weight. For adults over 35 with insulin resistance, significant metabolic dysfunction, or meaningful excess weight, GLP-1 therapy may be one of the highest-leverage pharmacological longevity protocols currently available — with the strongest human evidence base of any drug in this tier.

Senescent "zombie" cells accumulate with age and drive chronic inflammation. Senolytics selectively eliminate them. Dasatinib plus quercetin and fisetin are the most studied candidates. Human trials show measurable reduction in senescent cell burden. Whether this translates to meaningful healthspan extension in humans at population scale is still being established. Requires physician oversight — dasatinib is a chemotherapy agent with a real side effect profile.

Urolithin A activates mitophagy — the cellular process of clearing damaged mitochondria. Human trials have shown improvements in muscle endurance and mitochondrial function in older adults at 500mg daily. The mechanism addresses a genuine root cause of aging. Individual gut bacteria production of urolithin A from dietary sources varies dramatically, making supplementation more reliably effective than diet alone. Arguably stronger evidence than most longevity supplements in this tier.